Evidence map›Paper›PMID 20024637›Full record

ReviewHerz2009

Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges.

Mitja Lainscak, Markus S Anker, Stephan von Haehling, Stefan D Anker

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Emerging biomarkers in heart failure and cardiac cachexia.International journal of molecular sciences · 2014
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Use of multiple biomarkers in heart failure.Current cardiology reports · 2010
    Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mitja LainscakDivision of Applied Cachexia Research, Department of Cardiology, Campus Virchow Clinic, Charité - Universitätsmedizin, Berlin, Germany. mitja.lainscak@guest.arnes.si
Markus S Anker
Stephan von Haehling
Stefan D Anker

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac biomarkers are very important in diagnosis, risk stratification, and management of patients with heart failure. Although not meeting all criteria for an ideal biomarker, natriuretic peptides primarily have a diagnostic and prognostic role. Other routinely available and newly emerging biomarkers have a complementary role in patient management; thus multimarker strategy might be warranted in future. The quest for a single marker or a combination is ongoing and several established, widely available biomarkers might have been overlooked in the field of heart failure. The authors review some of those biomarkers and speculate on the possible roles of combining two or more of them.

Indexed as

BiomarkersChronic DiseaseHeart FailureHumansNatriuretic PeptidesPrognosisSensitivity and SpecificityBiomarkersNatriuretic Peptides

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.